- By ICR Secretariat
- Posted Thursday, June 30, 2022
UCB lowers 2022 profit expectations amid Ukraine war, rising costs
https://www.fiercepharma.com/pharma/ucb-updates-2022-financial-guidance-citing-external-headwinds
Generic competition, a complete response letter, a new acquisition and external pressures have created a perfect storm for UCB, leading the company to reduce its profit forecast for 2022.
The oldest independent membership-led professional body for clinical researchers across the globe.
Latest Posts
- NICE recommendation expands patient eligibility for AbbVie’s Ozurdex 18/08/2022 03:38 PM
- Amgen’s low tax rates draw attention of top Democratic senator 18/08/2022 03:23 PM
- 2 deaths after Novartis' Zolgensma put gene therapy's liver safety in the spotlight once again 18/08/2022 03:16 PM
Useful Links
Contact Us
Suite 11a, Cedar Court
Grove Park
White Waltham
Maidenhead
SL6 3LW
info@icr-global.org